Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 224

1.

Early Transcriptional Divergence Marks Virus-Specific Primary Human CD8+ T Cells in Chronic versus Acute Infection.

Wolski D, Foote PK, Chen DY, Lewis-Ximenez LL, Fauvelle C, Aneja J, Walker A, Tonnerre P, Torres-Cornejo A, Kvistad D, Imam S, Waring MT, Tully DC, Allen TM, Chung RT, Timm J, Haining WN, Kim AY, Baumert TF, Lauer GM.

Immunity. 2017 Oct 17;47(4):648-663.e8. doi: 10.1016/j.immuni.2017.09.006.

PMID:
29045899
2.

Qualitative differences in cellular immunogenicity elicited by hepatitis C virus T-Cell vaccines employing prime-boost regimens.

Tan WG, Zubkova I, Kachko A, Wells F, Adler H, Sutter G, Major ME.

PLoS One. 2017 Jul 21;12(7):e0181578. doi: 10.1371/journal.pone.0181578. eCollection 2017.

3.

Mouse models of acute and chronic hepacivirus infection.

Billerbeck E, Wolfisberg R, Fahnøe U, Xiao JW, Quirk C, Luna JM, Cullen JM, Hartlage AS, Chiriboga L, Ghoshal K, Lipkin WI, Bukh J, Scheel TKH, Kapoor A, Rice CM.

Science. 2017 Jul 14;357(6347):204-208. doi: 10.1126/science.aal1962.

PMID:
28706073
4.

Programmed Cell Death 1 (PD-1) and Cytotoxic T Lymphocyte-Associated Antigen 4 (CTLA-4) in Viral Hepatitis.

Cho H, Kang H, Lee HH, Kim CW.

Int J Mol Sci. 2017 Jul 13;18(7). pii: E1517. doi: 10.3390/ijms18071517. Review.

5.

Hurdles to the Development of Effective HBV Immunotherapies and HCV Vaccines.

Torres-Cornejo A, Lauer GM.

Pathog Immun. 2017;2(1):102-125. doi: 10.20411/pai.v2i1.201. Epub 2017 Apr 9.

6.

Broadening CD4+ and CD8+ T Cell Responses against Hepatitis C Virus by Vaccination with NS3 Overlapping Peptide Panels in Cross-Priming Liposomes.

Filskov J, Mikkelsen M, Hansen PR, Christensen JP, Thomsen AR, Andersen P, Bukh J, Agger EM.

J Virol. 2017 Jun 26;91(14). pii: e00130-17. doi: 10.1128/JVI.00130-17. Print 2017 Jul 15.

PMID:
28446674
7.

Fighting Viral Infections and Virus-Driven Tumors with Cytotoxic CD4+ T Cells.

Muraro E, Merlo A, Martorelli D, Cangemi M, Dalla Santa S, Dolcetti R, Rosato A.

Front Immunol. 2017 Feb 27;8:197. doi: 10.3389/fimmu.2017.00197. eCollection 2017. Review.

8.

Preclinical evaluation of multi antigenic HCV DNA vaccine for the prevention of Hepatitis C virus infection.

Lee H, Jeong M, Oh J, Cho Y, Shen X, Stone J, Yan J, Rothkopf Z, Khan AS, Cho BM, Park YK, Weiner DB, Son WC, Maslow JN.

Sci Rep. 2017 Mar 7;7:43531. doi: 10.1038/srep43531.

9.

Hepatitis C virus infection inhibits a Src-kinase regulatory phosphatase and reduces T cell activation in vivo.

Bhattarai N, McLinden JH, Xiang J, Mathahs MM, Schmidt WN, Kaufman TM, Stapleton JT.

PLoS Pathog. 2017 Feb 24;13(2):e1006232. doi: 10.1371/journal.ppat.1006232. eCollection 2017 Feb.

10.

Regulatory T Cells in Hepatitis B and C Virus Infections.

Jung MK, Shin EC.

Immune Netw. 2016 Dec;16(6):330-336. doi: 10.4110/in.2016.16.6.330. Epub 2016 Dec 22. Review.

11.

Treatment of Hepatitis C in Patients Undergoing Immunosuppressive Drug Therapy.

Ooka K, Lim JK.

J Clin Transl Hepatol. 2016 Sep 28;4(3):206-227. Epub 2016 Aug 10. Review.

12.

T Cell Distribution in Relation to HIV/HBV/HCV Coinfections and Intravenous Drug Use.

Kallas E, Huik K, Türk S, Pauskar M, Jõgeda EL, Šunina M, Karki T, Des Jarlais D, Uusküla A, Avi R, Lutsar I.

Viral Immunol. 2016 Oct;29(8):464-470. Epub 2016 Aug 26.

13.

Dynamics of PBMC gene expression in hepatitis C virus genotype 1-infected patients during combined peginterferon/ribavirin therapy.

Lu MY, Huang CI, Hsieh MY, Hsieh TJ, Hsi E, Tsai PC, Tsai YS, Lin CC, Hsieh MH, Liang PC, Lin YH, Hou NJ, Yeh ML, Huang CF, Lin ZY, Chen SC, Huang JF, Chuang WL, Dai CY, Yu ML.

Oncotarget. 2016 Sep 20;7(38):61325-61335. doi: 10.18632/oncotarget.11348.

14.

A Comprehensive Analysis of the Impact of HIV on HCV Immune Responses and Its Association with Liver Disease Progression in a Unique Plasma Donor Cohort.

Zhang YH, Zhao Y, Rajapaksa US, Lawrence TM, Peng YC, Liu J, Xu K, Hu K, Qin L, Liu N, Sun H, Yan HP, Repapi E, Rowland-Jones S, Thimme R, McKeating JA, Dong T.

PLoS One. 2016 Jul 25;11(7):e0158037. doi: 10.1371/journal.pone.0158037. eCollection 2016.

15.

Involvement of the Interleukin-23/Interleukin-17 Axis in Chronic Hepatitis C Virus Infection and Its Treatment Responses.

Meng P, Zhao S, Niu X, Fu N, Su S, Wang R, Zhang Y, Qiao L, Nan Y.

Int J Mol Sci. 2016 Jul 15;17(7). pii: E1070. doi: 10.3390/ijms17071070. Erratum in: Int J Mol Sci. 2016 Oct 26;17 (11):.

16.

Lessons from Nature: Understanding Immunity to HCV to Guide Vaccine Design.

Freeman ZT, Cox AL.

PLoS Pathog. 2016 Jun 30;12(6):e1005632. doi: 10.1371/journal.ppat.1005632. eCollection 2016 Jun. Review. No abstract available.

17.

A CCL5 Haplotype Is Associated with Low Seropositivity Rate of HCV Infection in People Who Inject Drugs.

Huik K, Avi R, Pauskar M, Kallas E, Jõgeda EL, Karki T, Rüütel K, Talu A, Abel-Ollo K, Uusküla A, Carrillo A, Ahuja SK, He W, Lutsar I.

PLoS One. 2016 Jun 15;11(6):e0156850. doi: 10.1371/journal.pone.0156850. eCollection 2016.

18.

Brief Report: CD14brightCD16- monocytes and sCD14 level negatively associate with CD4-memory T-cell frequency and predict HCV-decline on therapy.

Judge CJ, Sandberg JK, Funderburg NT, Sherman KE, Butt AA, Kang M, Landay AL, Lederman MM, Anthony DD.

J Acquir Immune Defic Syndr. 2016 Nov 1;73(3):258-262.

19.

Cellular immune response to hepatitis-C-virus in subjects without viremia or seroconversion: is it important?

Abdelwahab SF.

Infect Agent Cancer. 2016 May 16;11:23. doi: 10.1186/s13027-016-0070-0. eCollection 2016. Review.

20.

HCV Specific IL-21 Producing T Cells but Not IL-17A Producing T Cells Are Associated with HCV Viral Control in HIV/HCV Coinfection.

MacParland SA, Fadel SM, Mihajlovic V, Fawaz A, Kim C, Rahman AK, Liu J, Kaul R, Kovacs C, Grebely J, Dore GJ, Wong DK, Ostrowski MA.

PLoS One. 2016 Apr 28;11(4):e0154433. doi: 10.1371/journal.pone.0154433. eCollection 2016.

Supplemental Content

Support Center